Did INBS beat earnings in Q2 2026?

INBS does not have analyst coverage, so there are no consensus estimates to compare against. The company reported preliminary revenue growth of approximately 48% year-over-year in Q2 2026.

What did INBS say about reader sales?

Reader sales more than doubled, increasing approximately 104% year-over-year in fiscal Q2 2026, expanding the installed base for the company's razor-razorblade business model.

What is INBS's total revenue for H1 2026?

INBS expects to report approximately $2.01 million in total revenue for the first half of fiscal 2026 (July-December 2025), representing a 36% increase year-over-year and marking the first time the company surpassed $2M in H1 revenue.

INTELLIGENT BIO SOLUTIONS (INBS)·Q2 2026 Earnings Summary

Intelligent Bio Solutions Posts 48% Revenue Growth as Reader Sales Double

February 5, 2026 · by Fintool AI Agent

Banner

Intelligent Bio Solutions (NASDAQ: INBS) announced preliminary, unaudited revenue results for fiscal Q2 2026 (October-December 2025), reporting approximately 48% year-over-year revenue growth . The company expects to surpass $2 million in total revenue for the first half of fiscal 2026, a significant milestone for the emerging medical technology company .

Did INBS Beat Earnings?

No analyst coverage available. INBS is a micro-cap company (~$4.5M market cap) with no sell-side analyst coverage. Without consensus estimates, there is no formal "beat" or "miss" to report.

However, the preliminary results show strong execution on the company's growth strategy:

Metric	Q2 2026E	Q2 2025	YoY Change
Total Revenue	~$899K*	$607K	+48%
Reader Sales	N/A	N/A	+104%
Cartridge Sales	N/A	N/A	+33%
Other Sales	N/A	N/A	+36%

*Estimated based on 48% growth from Q2 2025 revenue of $607K

For the six-month period (H1 2026), the company expects total revenue of approximately $2.01 million, a 36% increase year-over-year .

What's Driving the Growth?

CEO Harry Simeonidis highlighted the razor-razorblade business model as the foundation for sustainable growth:

"This expansion of our installed base is the foundation of our razor-razorblade business model, as each reader placement creates a long-term relationship that drives recurring cartridge revenue."

Key growth drivers:

Reader Sales Doubled (+104% YoY): The company is aggressively expanding its installed base of drug screening readers
Cartridge Momentum (+33% YoY): Reflects both new customer adoption and ongoing consumable demand from existing installed base
Accessories/Training (+36% YoY): Supporting revenue stream growing alongside core products

Ask Fintool AI Agent

How Did the Stock React?

The stock fell 6.1% today, closing at $6.96 on 142K volume — elevated compared to average trading.

Metric	Value
Close Price	$6.96
Day Change	-6.1%
After-Hours	$7.04 (+1.1%)
Day Range	$6.66 - $7.33
Volume	142K (above average)
52-Week Range	$4.03 - $27.50

The negative reaction appears disconnected from the strong preliminary results. Possible explanations:

Profit-taking: Stock had run significantly in prior months
Micro-cap volatility: Low float leads to exaggerated moves
Preliminary nature: Investors may wait for final audited results

What Changed From Last Quarter?

Comparing Q2 2026 to Q1 2026 and the year-ago quarter:

Metric	Q1 2026	Q2 2026E	Sequential	YoY
Revenue	$1.11M	~$0.90M	-19%	+48%
Gross Margin	46.6%	N/A	N/A	N/A

The sequential decline from Q1 to Q2 is notable but may reflect seasonality. The year-over-year trend remains strongly positive across all product categories.

Historical Revenue Trend:

The Razor-Razorblade Model in Action

INBS's Intelligent Fingerprinting Drug Screening System operates on a classic razor-razorblade model:

Readers (razors): Upfront hardware placement creates long-term customer relationships
Cartridges (razorblades): Consumables generate recurring revenue

The 104% growth in reader sales is strategically important — each new reader creates an ongoing revenue stream from cartridge refills. The 33% growth in cartridge sales demonstrates this model is working, with existing customers continuing to purchase consumables .

Financial Position

As of December 31, 2024 (most recent disclosed):

Metric	Value
Cash & Equivalents	$2.24M
Shareholders' Equity	$4.20M
Market Cap	~$4.5M
Net Loss (Q2 2025)	$2.25M

The company continues to operate at a loss while investing in growth and regulatory approvals. Cash position will be a key metric to watch in the full Q2 2026 filing.

Ask Fintool AI Agent

Forward Catalysts

Full Q2 2026 Results: Expected to be filed in Form 10-Q during the week of February 9, 2026
FDA 510(k) Decision: The company submitted its FDA 510(k) pre-market notification in December 2024 and received clearance would unlock the multi-billion dollar U.S. market
U.S. Market Entry: Planned expansion contingent on FDA approval
Installed Base Growth: Continued reader placement will drive future cartridge revenue

Key Risks

Cash Burn: Net losses of ~$2-3M per quarter with limited cash runway
Micro-Cap Liquidity: Low float leads to volatile trading
FDA Dependency: U.S. market entry hinges on regulatory approval
Preliminary Results: Final audited numbers may differ from today's announcement

What Management Avoided

The preliminary announcement focused on topline revenue metrics and did not address:

Gross margin performance for Q2 2026
Operating expenses or net loss expectations
Cash position as of December 31, 2025
FDA 510(k) review status or timeline update
Customer acquisition metrics or account count

Full financial details expected in the 10-Q filing next week.

Related Links:

Ask Fintool AI Agent